They clarify pharmaceutical companies’ obligations and possibilities to inform, as well as the role to be played by Member States.
Parlamenta grozījumi pamatojas uz principiem, ka pacientiem ir tiesības saņemt precīzu un nesagrozītu informāciju par zālēm.